ARTICLE | Company News

Xenetic hematology news

April 21, 2014 7:00 AM UTC

In 1Q14, U.K.-based Xenetic Biosciences plc became U.S.-based Xenetic Biosciences Inc. In January, Xenetic Biosciences plc delisted from LSE and completed a reverse merger with Xenetic Biosciences Inc. (formerly General Sales and Leasing Inc.). In February, Xenetic Biosciences Inc. began trading on OTCBB under the ticker "XBIO." In March, the company relocated its headquarters to Lexington, Mass., from London, U.K. The company said it believes it will be "better able to attract and retain qualified scientific researchers and other staff in its new Lexington location due to the Boston area having a wealth of talent in orphan drug development and market launch expertise." Xenetic's ErepoXen is a long-acting erythropoietin (EPO) in Phase III testing for anemia in chronic kidney disease (CKD). ...